Quest DiagnosticsDGX.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 16, 2026, Quest Diagnostics (DGX.N) trades at a P/E of 24.40x, P/B of 3.42x, P/S of 2.24x, and a dividend yield of 1.44%.
Longitudinal percentile comparison: P/E sits at the 99th percentile over the trailing 10Y window (vs. 96th percentile over 3Y); P/B sits at the 99th percentile over the trailing 10Y window (vs. 96th percentile over 3Y); P/S sits at the 99th percentile over the trailing 10Y window (vs. 96th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 54th percentile within its industry and the 62nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.17%, ranking at the 13th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 0.0 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 3.17% total shareholder yield, 1.44% is paid out as dividends and roughly 1.73% is implied to come from buybacks — both channels are meaningfully in play. Quest Diagnostics operates in the Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: DGX · DGX
Want the full picture on whether Quest Diagnostics (DGX.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 24.40 | ||||||
| P/B (MRQ) | 3.42 | ||||||
| P/S (TTM) | 2.24 | ||||||
| Dividend Yield | 1.44% | ||||||
| Buyback + Div Yield | 3.17% |